Many community pharmacists are struggling to stock Adderall amid supply disruptions and high demand for the attention-deficit/hyperactivity disorder treatment, Bloomberg reported Aug. 18.
Among 358 community pharmacy leaders polled between July 25 and Aug. 5, 64 percent said brand name and generic versions of Adderall were on backorder, a survey from the National Community Pharmacists Association found.
In late July, Teva Pharmaceuticals told Blomberg it was experiencing "supply disruptions" of the drug. The company, which is the largest Adderall supplier in the U.S., said it expects supply levels to normalize in the next few weeks.
In 2021, the U.S. saw 41 million prescriptions for Adderall, marking a 10 percent increase from the year prior, according to data from Symphony Health cited by Bloomberg.